1
|
Vandeva S, Jaffrain-Rea ML, Daly AF,
Tichomirowa M, Zacharieva S and Beckers A: The genetics of
pituitary adenomas. Best Pract Res Clin Endocrinol Metab.
24:461–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Melmed S: Pathogenesis of pituitary
tumors. Nat Rev Endocrinol. 7:257–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Asa SL and Ezzat S: The pathogenesis of
pituitary tumors. Annu Rev Pathol. 4:97–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Douglas KR, Brinkmeier ML, Kennell JA, et
al: Identification of members of the Wnt signaling pathway in the
embryonic pituitary gland. Mamm Genome. 12:843–851. 2001.
View Article : Google Scholar
|
5
|
Brinkmeier ML, Potok MA, Cha KB, et al:
TCF and Groucho-related genes influence pituitary growth and
development. Mol Endocrinol. 17:2152–2161. 2003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Kioussi C, Briata P, Baek SH, et al:
Identification of a Wnt/Dvl/beta-Catenin → Pitx2 pathway mediating
cell-type-specific proliferation during development. Cell.
111:673–685. 2002. View Article : Google Scholar : PubMed/NCBI
|
7
|
Brinkmeier ML, Potok MA, Davis SW and
Camper SA: TCF4 deficiency expands ventral diencephalon signaling
and increases induction of pituitary progenitors. Dev Biol.
311:396–407. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Zeng YA and Nusse R: Wnt proteins are
self-renewal factors for mammary stem cells and promote their
long-term expansion in culture. Cell Stem Cell. 6:568–577. 2010.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–1851. 2000.PubMed/NCBI
|
10
|
Reed KR, Athineos D, Meniel VS, et al:
B-catenin deficiency, but not Myc deletion, suppresses the
immediate phenotypes of APC loss in the liver. Proc Natl Acad Sci
USA. 105:18919–18923. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Willert K and Jones KA: Wnt signaling: is
the party in the nucleus? Genes Dev. 20:1394–1404. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Gaston-Massuet C, Andoniadou CL, Signore
M, et al: Increased Wingless (Wnt) signaling in pituitary
progenitor/stem cells gives rise to pituitary tumors in mice and
humans. Proc Natl Acad Sci USA. 108:11482–11487. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Li W, Zhang Y, Zhang M, Huang G and Zhang
Q: Wnt4 is over-expressed in human pituitary adenomas and is
associated with tumor invasion. J Clin Neurosci. 21:137–141. 2014.
View Article : Google Scholar
|
15
|
Benjamin JM and Nelson WJ: Bench to
bedside and back again: molecular mechanisms of alpha-catenin
function and roles in tumorigenesis. Semin Cancer Biol. 18:53–64.
2008. View Article : Google Scholar
|
16
|
Kalani MY, Cheshier SH, Cord BJ, et al:
Wnt-mediated self-renewal of neural stem/progenitor cells. Proc
Natl Acad Sci USA. 105:16970–16975. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Nusse R: Wnt signaling and stem cell
control. Cell Res. 18:523–527. 2008. View Article : Google Scholar : PubMed/NCBI
|
18
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu RevCell Dev Biol.
20:781–810. 2004. View Article : Google Scholar
|
19
|
Cadigan KM and Peifer M: Wnt signaling
from development to disease: insights from model systems. Cold
Spring Harb Perspect Biol. 1:a0028812009. View Article : Google Scholar :
|
20
|
Park GB, Kim DJ, Kim YS, Lee HK, Kim CW
and Hur DY: Silencing of galectin-3 represses osteosarcoma cell
migration and invasion through inhibition of FAK/Src/Lyn activation
and beta-catenin expression and increases susceptibility to
chemotherapeutic agents. Int J Oncol. 46:185–194. 2015.
|
21
|
Bai XL, Zhang Q, Ye LY, et al: Myocyte
enhancer factor 2C regulation of hepatocellular carcinoma via
vascular endothelial growth factor and Wnt/beta-catenin signaling.
Oncogene. Oct 20–2014.(Epub ahead of print). View Article : Google Scholar
|
22
|
Salaroli R, Ronchi A, Buttarelli FR, et
al: Wnt activation affects proliferation, invasiveness and
radiosensitivity in medulloblastoma. J Neurooncol. Sep
28–2014.(Epub ahead of print). PubMed/NCBI
|
23
|
Gao ZH, Lu C, Wang MX, Han Y and Guo LJ:
Differential beta-catenin expression levels are associated with
morphological features and prognosis of colorectal cancer. Oncol
Lett. 8:2069–2076. 2014.PubMed/NCBI
|
24
|
Sareddy GR, Panigrahi M, Challa S,
Mahadevan A and Babu PP: Activation of Wnt/beta-catenin/Tcf
signaling pathway in human astrocytomas. Neurochem Int. 55:307–317.
2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Trovato M, Torre ML, Ragonese M, et al:
HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3
pathways in pituitary adenomas: an immunohistochemical
characterization in view of targeted therapies. Endocrine.
44:735–743. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Ma PC, Tretiakova MS, Nallasura V,
Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and
specific inhibition of c-MET/HGF pathway in small cell lung cancer:
implications for tumour invasion. Br J Cancer. 97:368–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Liotta LA and Kohn EC: The
microenvironment of the tumour-host interface. Nature. 411:375–379.
2001. View
Article : Google Scholar : PubMed/NCBI
|
28
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
29
|
de Aguiar PH, Aires R, Laws ER, et al:
Labeling index in pituitary adenomas evaluated by means of MIB-1:
is there a prognostic role? A critical review. Neurol Res.
32:1060–1071. 2010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Cully M, You H, Levine AJ and Mak TW:
Beyond PTEN mutations: the PI3K pathway as an integrator of
multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192.
2006. View
Article : Google Scholar : PubMed/NCBI
|
31
|
Fu Y, Zhang Q, Kang C, et al: Inhibitory
effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the
growth of malignant tumor cells in vitro and in vivo. Int J Oncol.
35:583–591. 2009.PubMed/NCBI
|
32
|
Yue X, Lan F, Yang W, et al: Interruption
of beta-catenin suppresses the EGFR pathway by blocking multiple
oncogenic targets in human glioma cells. Brain Res. 1366:27–37.
2010. View Article : Google Scholar : PubMed/NCBI
|
33
|
Dechow TN, Pedranzini L, Leitch A, et al:
Requirement of matrix metalloproteinase-9 for the transformation of
human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA.
101:10602–10607. 2004. View Article : Google Scholar : PubMed/NCBI
|
34
|
Silver DL, Naora H, Liu J, Cheng W and
Montell DJ: Activated signal transducer and activator of
transcription (STAT) 3: localization in focal adhesions and
function in ovarian cancer cell motility. Cancer Res. 64:3550–3558.
2004. View Article : Google Scholar : PubMed/NCBI
|
35
|
Senft C, Priester M, Polacin M, et al:
Inhibition of the JAK-2/STAT3 signaling pathway impedes the
migratory and invasive potential of human glioblastoma cells. J
Neurooncol. 101:393–403. 2011. View Article : Google Scholar
|
36
|
Wang J, Li X, Lu X and Pi L: The
regulation of stat3 signal transduction pathway to G1 to S phase of
laryngocarcinoma cell. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za
Zhi. 22:699–703. 2008.(In Chinese). PubMed/NCBI
|
37
|
Liu W, Kunishio K, Matsumoto Y, Okada M
and Nagao S: Matrix metalloproteinase-2 expression correlates with
cavernous sinus invasion in pituitary adenomas. J Clin Neurosci.
12:791–794. 2005. View Article : Google Scholar : PubMed/NCBI
|
38
|
Gong J, Zhao Y, Abdel-Fattah R, et al:
Matrix metallopro-teinase-9, a potential biological marker in
invasive pituitary adenomas. Pituitary. 11:37–48. 2008. View Article : Google Scholar
|